Topics

FDA filings for bluebird bio's LentiGlobin, Lenti-D pushed back until mid-2021 by #COVID19 https://www.firstwordpharma.com/node/1710864  $BLUE

07:56 EDT 26 Mar 2020 | FirstWord Pharma

FDA filings for bluebird bio's LentiGlobin, Lenti-D pushed back until mid-2021 by https://www.firstwordpharma.com/node/1710864 

Original Article: FDA filings for bluebird bio's LentiGlobin, Lenti-D pushed back until mid-2021 by #COVID19 https://www.firstwordpharma.com/node/1710864  $BLUE

NEXT ARTICLE

More From BioPortfolio on "FDA filings for bluebird bio's LentiGlobin, Lenti-D pushed back until mid-2021 by #COVID19 https://www.firstwordpharma.com/node/1710864  $BLUE"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...